PepGen (PEPG) Gains from Investment Securities (2021 - 2022)

PepGen (PEPG) reported Gains from Investment Securities of -$58000.0 for Q1 2022, up 6.45% sequentially from -$62000.0 in Q4 2021.

PepGen (PEPG) Gains from Investment Securities (2021 - 2022) Analysis & Trends

PepGen (PEPG) has 2 years of Gains from Investment Securities data on file, last reported at -$58000.0 in Q1 2022.

For the quarter ending Q1 2022, Gains from Investment Securities changed N/A year-over-year to -$58000.0; the trailing twelve-month figure through Dec 2022 stood at -$58000.0 (changed N/A YoY), and the FY2022 full-year result was -$58000.0, down 129.59% from the prior year.
Gains from Investment Securities improved to -$58000.0 in Q1 2022, from -$62000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $65000.0 in Q3 2021 to a low of -$62000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,583.17 Bn	67,582.89 Bn	-
2	Nanobiotix	1,947.22 Bn	1,947.15 Bn	-
3	Akari Therapeutics	1,132.35 Bn	1,132.35 Bn	-
4	BeOne Medicines	473.21 Bn	468.42 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.29 Bn	116.04 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.05 Bn	61.29 Bn	3.31 Bn
7	Belite Bio	63.09 Bn	63.09 Bn	-
8	Argenx Se	56.63 Bn	51.45 Bn	1.41 Bn
9	Revolution Medicines	37.79 Bn	37.79 Bn	-
10	PepGen	135.07 Mn	135.07 Mn	-

Download Data